Top

International Journal of Colorectal Disease

Published in:

01-05-2009 | Original Article

Effects of cyclooxygenase inhibition on anastomotic healing following large bowel resection in a rabbit model—a randomized, blinded, placebo-controlled trial

Authors: Heiko Neuss, Wieland Raue, Verena Müller, Wilko Weichert, Wolfgang Schwenk, Julian W. Mall

Published in: International Journal of Colorectal Disease | Issue 5/2009

Abstract

Purpose

We performed an experimental study in a rabbit model to investigate the effects of a selective Cox-2 inhibitor (Valdecoxib) on anastomotic healing following large bowel resection after 1 week.

Materials and methods

Eighty New Zealand white rabbits were randomized into four groups and underwent a colon resection with end-to-end anastomosis. Group 1 (n = 20) was treated with Valdecoxib, group 2 with Metamizole (Novalgin®), group 3 with Resveratrol (specific Cox-1 inhibitor), or a placebo vehicle with similar volume (group 4). Anastomotic healing was tested at the seventh postoperative day by measurement of the bursting pressure in vitro. Immunohistochemical staining of the anastomotic site was performed with polyclonal antibodies (CD31).

Results

There were no significant differences in anastomotic dehiscence, bursting pressure, or vessel density between the treatment and control groups.

Conclusion

The application of Valdecoxib does not influence anastomotic healing or new vessel formation in the anastomotic region following large bowel resection.

Marusch F, Koch A, Schmidt U et al (2001) Effect of caseload on the short-term outcome of colon surgery: results of a multicenter study. Int J Colorectal Dis 16:362–369PubMedCrossRef

Tyrell J, Silberman H, Chandrasoma P et al (1989) Absorbable versus permanent mesh in abdominal operations. Surg Gynecol Obstet 168:227–232PubMed

Brune K, Hinz B (2004) The discovery and development of antiinflammatory drugs. Arthritis Rheum 50:2391–2399PubMedCrossRef

Gasparini G, Longo R, Sarmiento R et al (2003) Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol 4:605–615PubMedCrossRef

Araki Y, Okamura S, Hussain SP et al (2003) Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res 63:728–734PubMed

Dannenberg AJ, Altorki NK, Boyle JO et al (2001) Cyclo-oxygenase 2: a pharmacologicaltarget for the prevention of cancer. Lancet Oncol 2:544–551PubMedCrossRef

Diaz A, Chepenik KP, Korn JH et al (1998) Differential regulation of cyclooxygenases 1 and 2 by interleukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta 1 in human lung fibroblasts. Exp Cell Res 241:222–229PubMedCrossRef

Lin DT, Subbaramaiah K, Shah JP et al (2002) Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck 24:792–799PubMedCrossRef

Mobius C, Stein HJ, Spiess C et al (2005) COX2 expression, angiogenesis, proliferation and survival in Barrett’s cancer. Eur J Surg Oncol 31:755–759, (Cox Inhibition and Anastomotic Healing)PubMedCrossRef

10.

Moraitis D, Du B, De Lorenzo MS et al (2005) Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands. Cancer Res 65:664–670PubMed

11.

Juni P, Nartey L, Reichenbach S et al (2004) Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364:2021–2029PubMedCrossRef

12.

Mamdani M, Juurlink DN, Lee DS et al (2004) Cyclo-oxygenase-2 inhibitors versus nonselective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 363:1751–1756PubMedCrossRef

13.

Hendriks T, Mastboom WJ (1990) Healing of experimental intestinal anastomoses. Parameters for repair. Dis Colon Rectum 33:891–901PubMedCrossRef

14.

Abramson S, Edelson H, Kaplan H et al (1984) The inactivation of the polymorphonuclear leukocyte by non-steroidal anti-inflammatory drugs. Inflammation 8(Suppl):S103–S108PubMedCrossRef

15.

Goodwin JS (1984) Immunologic effects of nonsteroidal anti-inflammatory drugs. Am J Med 77:7–15PubMedCrossRef

16.

Horwitz AL, Hance AJ, Crystal RG (1977) Granulocyte collagenase: selective digestion of type I relative to type III collagen. Proc Natl Acad Sci U S A 74:897–901PubMedCrossRef

17.

Mastboom WJ, Hendriks T, van EP et al (1991) The influence of NSAIDs on experimental intestinal anastomoses. Dis Colon Rectum 34:236–243PubMedCrossRef

18.

Werb Z, Gordon S (1975) Secretion of a specific collagenase by stimulated macrophages. J Exp Med 142:346–360, (Cox Inhibition and Anastomotic Healing)PubMedCrossRef

19.

Muller-Decker K, Hirschner W, Marks F et al (2002) The effects of cyclooxygenase isozyme inhibition on incisional wound healing in mouse skin. J Invest Dermatol 119:1189–1195PubMedCrossRef

20.

Szewczuk LM, Forti L, Stivala LA et al (2004) Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: a mechanistic approach to the design of COX-1 selective agents. J Biol Chem 279:22727–22737PubMedCrossRef

21.

Altman DG (1991) Statistical analysis of comparison between laboratory methods. J Clin Pathol 44:700–701PubMedCrossRef

22.

Altman DG, Dore CJ (1991) Baseline comparisons in randomized clinical trials. Stat Med 10:797–799PubMedCrossRef

23.

Mall JW, Schwenk W, Philipp AW et al (2003) Intraperitoneal administration of the angiogenesis inhibitor thalidomide does not impair anastomotic healing following large bowel resection in a rabbit model. World J Surg 27:1119–1123PubMedCrossRef

24.

Muscara MN, McKnight W, Asfaha S et al (2000) Wound collagen deposition in rats: effects of an NO-NSAID and a selective COX-2 inhibitor. Br J Pharmacol 129:681–686PubMedCrossRef

25.

Zwingenberger K, Wnendt S (1995) Immunomodulation by thalidomide: systematic review of the literature and of unpublished observations. J Inflamm 46:177–211PubMed

26.

Nahai F, Lamb JM, Havican RG et al (1977) Factors involved in disruption of intestinal anastomoses. Am Surg 43:45–51PubMed

27.

Wise L, McAlister W, Stein T et al (1975) Studies on the healing of anastomoses of small and large intestines. Surg Gynecol Obstet 141:190–194PubMed

28.

Cahill RA, Sheehan KM, Scanlon RW et al (2004) Effects of a selective cyclo-oxygenase 2 inhibitor on colonic anastomotic and skin wound integrity. Br J Surg 91:1613–1618PubMedCrossRef

29.

Jiang C, Ting AT, Seed B (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82–86PubMedCrossRef

30.

Ricote M, Huang JT, Welch JS et al (1999) The peroxisome proliferator-activated receptor(PPARgamma) as a regulator of monocyte/macrophage function. J Leukoc Biol 66:733–739PubMed

31.

Simon AM, Manigrasso MB, O’Connor JP (2002) Cyclo-oxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 17:963–976PubMedCrossRef

32.

Dannenberg AJ, Altorki NK, Boyle JO et al (2001) Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2:544–551PubMedCrossRef

33.

Brasken P, Lehto M, Renvall S (1989) Changes in the connective tissue composition of the submucosal layer of colonic anastomosis. An immunohistologic study in rats. Acta Chir Scand 155:413–419PubMed

34.

Lindner J (1982) [Morphology and biochemistry of wound healing]. Langenbecks Arch Chir 358:153–160PubMedCrossRef

35.

de Sousa JB, Soares EG, Aprilli F (1991) Effects of diclofenac sodium on intestinal anastomotic healing. Experimental study on the small intestine of rabbits. Dis Colon Rectum 34:613–617PubMedCrossRef

36.

Campos C, de GR, Garcia-Nieto R et al (1999) Regulation of cyclooxygenase activity by metamizol. Eur J Pharmacol 378:339–347PubMedCrossRef

37.

Langford RM, Mehta V (2006) Selective cyclooxygenase inhibition: its role in pain and anaesthesia. Biomed Pharmacother 60:323–328PubMedCrossRef

38.

Asensi M, Medina I, Ortega A et al (2002) Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med 33:387–398PubMedCrossRef

39.

Bhattacharyya DK, Lecomte M, Dunn J et al (1995) Selective inhibition of prostaglandin endoperoxide synthase-1 (cyclooxygenase-1) by valerylsalicylic acid. Arch Biochem Biophys 317:19–24PubMedCrossRef

40.

de Hingh I, van Goor H, de Man BM et al (2006) Selective cyclo-oxygenase 2 inhibition affects ileal but not colonic anastomotic healing in the early postoperative period. Br J Surg 93:489–497PubMedCrossRef

Title: Effects of cyclooxygenase inhibition on anastomotic healing following large bowel resection in a rabbit model—a randomized, blinded, placebo-controlled trial
Authors: Heiko Neuss
Wieland Raue
Verena Müller
Wilko Weichert
Wolfgang Schwenk
Julian W. Mall
Publication date: 01-05-2009
Publisher: Springer-Verlag
Published in: International Journal of Colorectal Disease / Issue 5/2009
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-009-0643-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Effects of cyclooxygenase inhibition on anastomotic healing following large bowel resection in a rabbit model—a randomized, blinded, placebo-controlled trial

Abstract

Purpose

Materials and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2009

Surgeons lack predictive accuracy for anastomotic leakage in gastrointestinal surgery

Small intestinal submucosa for reinforcement of colonic anastomosis

Idiopathic pseudomembranous colitis limited to the right colon: a change from Clostridium difficile

Meta-analysis of medical treatment and placebo treatment for preventing postoperative recurrence in Crohn’s disease (CD)

Sham feed or sham? A meta-analysis of randomized clinical trials assessing the effect of gum chewing on gut function after elective colorectal surgery

Chronic inflammatory demyelinating polyradiculoneuropathy associated with inflammatory bowel diseases: questioning the autoimmunity hypothesis